CCEL

Cryo-Cell International, Inc. - 10-Q Summary

Business Context and Reporting Period

This is a quarterly report (Form 10-Q) for Cryo-Cell International, Inc., a smaller reporting company engaged in cellular processing and cryogenic storage, primarily focusing on umbilical cord blood stem cells (U-Cord) and menstrual stem cells (C'elle). The reporting period covers the three and six months ended May 31, 2009.

Key Financial Metrics

Liquidity: The company holds $5.15 million in cash and cash equivalents and $1.16 million in marketable securities. Management anticipates these resources, combined with operating cash flows, will be sufficient to fund operations for at least the next 12 months.

Material Changes vs. Prior Period

• Profitability Turnaround: The company reported a net income of $1.27 million for the six months ended May 31, 2009, compared to a net loss of $603,000 in the same period in 2008. This shift was driven by significant expense reductions.
• Revenue Decline: Total revenue decreased by 7% year-over-year. This was primarily due to a 13% decrease in the number of specimens processed and a 13% increase in sales discounts, partially offset by a 10% increase in recurring annual storage fees.
• Expense Reductions:
  • Marketing, General & Administrative (MG&A) expenses decreased 25% to $4.31 million, attributed to reduced operational expenses and improved efficiencies.
  • Cost of sales decreased 25% to $2.29 million, driven by lower specimen volume and operational cost cuts.
  • Research and Development expenses decreased 38% to $58,320, as the initial commercialization costs for the C'elle technology (launched in late 2007) subsided.
• Licensee Income: Increased 56% to $725,353, driven by royalty income and installment payments from licensees in India and Venezuela.

Outlook, Risks, and Contingencies

• Guidance: Management anticipates non-discretionary capital expenditures of approximately $300,000 over the next twelve months, funded by operating cash flows. No specific revenue guidance was provided.
• Legal Proceedings: The company is involved in patent litigation with PharmaStem Therapeutics, Inc. The U.S. Court of Appeals for the Federal Circuit previously ruled in Cryo-Cell's favor regarding two patents, and the Supreme Court denied certiorari. A second case involving two other patents was stayed pending U.S. PTO re-examination, which resulted in the cancellation of all claims for those patents. Cryo-Cell intends to seek dismissal of the second case.
• Revenue Sharing Agreements (RSAs): The company has four RSAs covering New York, Texas, Florida, and Illinois. These agreements require the company to share a percentage of future storage revenue in perpetuity. Interest expense related to these agreements was $687,823 for the six-month period.
• Warranty Reserves: The company maintains a reserve of approximately $119,000 for its "Cryo-Cell Cares" program, which offers financial compensation if stored stem cells fail to engraft. No claims have been made to date.
• Risk Factors: Key risks include increased government regulation of stem cell storage, competition, market acceptance of new technologies (C'elle), and the financial stability of international licensees.

Investor Verification Checklist

• Revenue Quality: Verify the sustainability of the 10% increase in recurring storage fees against the 13% decline in new specimen processing.
• Expense Trajectory: Confirm if the 25% reduction in MG&A expenses is a permanent structural change or a temporary measure.
• Licensee Performance: Monitor the financial health of international licensees (India, Venezuela) to ensure continued royalty and installment payments.
• Legal Finality: Confirm the formal dismissal of the second PharmaStem litigation case following the patent cancellations.
• Warranty Exposure: Assess the assumptions used for the $119,000 warranty reserve, particularly regarding engraftment failure rates.